Related Experiment Video

Updated: Aug 16, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Gefitinib is also active for carcinomatous meningitis in NSCLC

Min Kyoung Kim1, Kyung Hee Lee, Jae Kyo Lee

  • 1Department of Internal Medicine, Yeungnam University College of Medicine, Namgu, Daegu, South Korea.

Lung Cancer (Amsterdam, Netherlands)
|July 19, 2005
PubMed

Insights

Gefitinib shows promise in treating carcinomatous meningitis and spinal cord metastases in non-small cell lung cancer patients. This case report highlights a positive response in a heavily pretreated individual, suggesting potential efficacy despite limited data.

Area of Science:

  • Oncology
  • Neuro-oncology

Background:

  • Carcinomatous meningitis (CM) and spinal cord metastases (SCM) are severe complications of non-small cell lung cancer (NSCLC).
  • Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is a targeted therapy for NSCLC.
  • Limited data exist on gefitinib's efficacy and blood-brain barrier penetration for CNS metastases.

Observation:

  • A 59-year-old male patient with heavily pretreated non-small cell lung cancer presented with carcinomatous meningitis and spinal cord metastases.
  • The patient received gefitinib treatment.

Findings:

  • The patient exhibited a good clinical response to gefitinib.
  • This suggests potential efficacy of gefitinib in managing CM and SCM in NSCLC.

Implications:

  • Gefitinib may be a viable treatment option for NSCLC patients with CNS metastases, including CM and SCM.
  • Further research is warranted to confirm gefitinib's efficacy and safety in this patient population.
  • Understanding gefitinib's blood-brain barrier penetration is crucial for optimizing its use in neuro-oncology.

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...